Hydrea, Hydroxyurea Newswire

Hydrea, Hydroxyurea Newswire

Comprehensive Real-Time News Feed for Hydrea, Hydroxyurea (generic).

Results 1 - 20 of 217 in Hydrea, Hydroxyurea (generic)

  1. Global Blood Therapeutics: ASH UpdateRead the original story w/Photo

    Tuesday Dec 12 | Seeking Alpha

    Shares dipped on reports of two patient deaths but appeared to recover as Wall Street realized they were not drug related. While it could make sense to take some risk off the table, I suggest buying a pilot position or retaining a significant portion of shares for the run up into Hope Part A data.

    Comment?

  2. 4 Possible Biotech Takeover Targets for 2018Read the original story w/Photo

    Monday Dec 11 | BioSpace

    This year wasn't big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016. Many industry watchers and investors are paying close attention to Congress' tax plan, which would potentially cut the corporate tax rate from about 35 percent to 20 percent, and would allow companies to repatriate funds from overseas accounts at a one-time tax rate of 10 percent.

    Comment?

  3. Sickle-cell disease gets rush of gene-based researchRead the original story w/Photo

    Tuesday Dec 12 | Chicago Tribune

    Under a high magnification of 8000X, this scanning electron micrograph revealed some of the ultra structural morphology displayed by red blood cells of a 6 year old male patient with sickle cell anemia. Under a high magnification of 8000X, this scanning electron micrograph revealed some of the ultra structural morphology displayed by red blood cells of a 6 year old male patient with sickle cell anemia.

    Comment?

  4. Agios Pharma's ivosidenib shows positive effect in early-stage AML study; shares ahead 3% after hoursRead the original story w/Photo

    Monday Dec 11 | Seeking Alpha

    Results from a Phase 1 dose-escalation and expansion study assessing Agios Pharmaceuticals' ivosidenib in patients with relapsed/refractory acute myeloid leukemia with a genetic mutation called IDH1 showed a treatment benefit. The data were presented at ASH in Atlanta.

    Comment?

  5. Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy DataRead the original story w/Photo

    Monday Dec 11 | Benzinga

    Global Blood Therapeutics Inc , a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition. Global Blood's interim data for its Phase 2a trial of the sickle cell disease therapy GBT440 in adolescents was consistent with prior adult results and demonstrates efficacy on top of hydroxyurea and utility of the PRO, Harrison said in a Sunday note.

    Comment?

  6. bluebird bio Presents Updated Data from HGB-205 Study of...Read the original story

    Monday Dec 11 | Customer Interaction Solutions

    The findings will be presented today in a poster session at the 59th Annual Meeting of the American Society of Hematology . "People with SCD and TDT experience serious complications and organ damage as a result of their disease and complications from chronic blood transfusions.

    Comment?

  7. Four-Year Phase 3 Data Analysis Shows Durability of Response of...Read the original story

    Sunday Dec 10 | Customer Interaction Solutions

    Incyte Corporation today announced new 208-week follow-up data from the ongoing, global, multi-center, open-label Phase 3 RESPONSE study of Jakafi comparing the efficacy and safety of Jakafi with best available therapy in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea . The pre-planned data analysis showed a durable primary response to Jakafi in patients with PV who are resistant to or intolerant of HU and the overall safety profile for Jakafi remained consistent with previously reported 80-week RESPONSE data.1 The results were shared in an oral presentation today at the 59th American Society of Hematology Annual Meeting 2017 in Atlanta, Georgia.

    Comment?

  8. GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell DiseaseRead the original story w/Photo

    Saturday Dec 9 | GlobeNewswire

    Global Blood Therapeutics, Inc. today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, voxelotor , a potentially disease-modifying therapy for adolescents with sickle cell disease . These data will be highlighted today during a press briefing at the 59th American Society of Hematology Annual Meeting & Exposition and will also be presented during an oral session on Monday, December 11, at 3:45 p.m. Eastern Time in Building B, Level 3, B308-B309 of the Georgia World Congress Center in Atlanta.

    Comment?

  9. Significant Economic Burden Associated With Various AML Treatment EpisodesRead the original story w/Photo

    Friday Dec 8 | The American Journal of Managed Care

    Acute myeloid leukemia treatment episodes such as high-intensity chemotherapy, low-intensity chemotherapy, hematopoietic stem cell transplant, and relapsed-refractory patient episodes pose a significant substantial burden, according to an analysis presented at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. There is a substantial economic burden associated with multiple acute myeloid leukemia treatment episodes, according to an analysis presented at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

    Comment?

  10. Global Blood Therapeutics: Hopeful UncertaintyRead the original story w/Photo

    Thursday Dec 7 | Seeking Alpha

    Using Filip De Ridder's statistical modeling and methodology in predicting phase 3 trials using phase 2 criterion, we attempt to bring more clarity to voxelotor's prospects, but end up with more questions. Investors taking a stake in Global Blood Therapeutics are investing in an especially unknown, binary event and should limit risk exposure accordingly.

    Comment?

  11. Analyzing IncyteRead the original story w/Photo

    Wednesday Dec 6 | The Breeze

    Incyte and Roka Bioscience are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. 90.9% of Incyte shares are held by institutional investors.

    Comment?

  12. Incyte (INCY) versus The Competition Head-To-Head ReviewRead the original story w/Photo

    Monday Dec 4 | Daily Political

    Incyte is one of 188 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it contrast to its rivals? We will compare Incyte to related businesses based on the strength of its valuation, analyst recommendations, risk, profitability, dividends, earnings and institutional ownership. 90.9% of Incyte shares are held by institutional investors.

    Comment?

  13. Contrasting IncyteRead the original story w/Photo

    Sunday Dec 3 | AmericanBankingNews.com

    Incyte and Roka Bioscience are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Incyte has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

    Comment?

  14. Head to Head Comparison: Incyte (INCY) and Its CompetitorsRead the original story w/Photo

    Friday Dec 1 | AmericanBankingNews.com

    Incyte is one of 189 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it weigh in compared to its rivals? We will compare Incyte to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, analyst recommendations and dividends. Incyte currently has a consensus price target of $145.63, suggesting a potential upside of 47.12%.

    Comment?

  15. Incyte Corporation (INCY) vs. Its Rivals Critical AnalysisRead the original story w/Photo

    Wednesday Nov 22 | Daily Political

    Incyte Corporation is one of 187 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it compare to its rivals? We will compare Incyte Corporation to related companies based on the strength of its dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. 89.6% of Incyte Corporation shares are held by institutional investors.

    Comment?

  16. CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell DiseaseRead the original story w/Photo

    Wednesday Nov 22 | Centers for Disease Control and Prevention

    Mary Hulihan, DrPH1; Kathryn L. Hassell, MD2; Jean L. Raphael, MD3; Kim Smith-Whitley, MD4; Phoebe Thorpe, MD5 Approximately 100,000 Americans have sickle cell disease , a group of recessively inherited red blood cell disorders characterized by abnormal hemoglobin, called hemoglobin S or sickle hemoglobin, in the red blood cells. Persons with hemoglobin SS or hemoglobin SAY0 thalassemia, also known as sickle cell anemia , have the most severe form of SCD.

    Comment?

  17. Loyola Medicine Helps Pediatric Sickle Cell Patient Take Trip of a LifetimeRead the original story w/Photo

    Tuesday Nov 21 | Newswise

    Anyah wasn't going to let sickle cell disease keep her from going on her high school class trip to Europe. Thanks to Natalie Kamberos, DO, and the care Anyah received at Loyola Medicine, Anyah was able to climb the Eiffel Tower and make it a trip of a lifetime.

    Comment?

  18. Sickle Cell Disease Market - Expected to Rise at a Remarkable CAGR By 2025Read the original story

    Sunday Nov 19 | Emailwire.com

    Market Insights, Epidemiology and Market Forecast-2025' report provides an overview of Sickle Cell Disease, epidemiology and market trends of the Sickle Cell Disease for the United States and EU5 . The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Sickle Cell Disease from 2017 to 2025 segmented by seven major markets.

    Comment?

  19. Analyzing Incyte Corporation (INCY) and Its RivalsRead the original story w/Photo

    Thursday Nov 16 | AmericanBankingNews.com

    Incyte Corporation is one of 186 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it weigh in compared to its rivals? We will compare Incyte Corporation to similar companies based on the strength of its earnings, risk, profitability, analyst recommendations, dividends, valuation and institutional ownership. This is a summary of recent recommendations and price targets for Incyte Corporation and its rivals, as provided by MarketBeat.com.

    Comment?

  20. Sickle Cell Disease Treatment Market to Represent a Value of US $584.0 Mn by the End of 2025Read the original story w/Photo

    Wednesday Nov 15 | SBWire

    Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing adoption of therapies, growing awareness regarding the sickle cell disease treatment in MEA region.

    Comment?